The private pain specialist is interested in business development opportunities in its core therapeutic space and adjacencies, but also looking at other ‘innovative’ technologies and partnerships with ex-US drug manufacturers, CEO Timney said during an interview.
Purdue Pharma LP’s initiative to diversify includes business deals on multiple fronts, including in its core area of pain but also in new “innovative” areas and through commercialization deals with ex-US partners, CEO Mark Timney said in a recent interview.
The chief executive has set deal-making as a top priority for Purdue since taking over the helm of the private...
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
